Cell Cycle Checkpoints: A Guide to G1, G2, and M Phase Regulation

Cell cycle checkpoints are surveillance mechanisms that monitor the order, integrity, and fidelity of major cell cycle events, including growth to appropriate cell size, chromosome replication and integrity, and accurate chromosome segregation at mitosis. These checkpoints operate at defined transition points, primarily the G1/S boundary, the G2/M boundary, and the metaphase to anaphase transition, and they determine whether a cell proceeds, pauses, or exits the cycle. For laboratory students, technicians, researchers, and diagnostic professionals, understanding these regulatory circuits is essential for interpreting cell proliferation assays, designing experiments that synchronize cells, evaluating compounds that arrest the cell cycle, and recognizing how checkpoint dysfunction contributes to disease states such as cancer. This article explains the molecular regulators at each checkpoint, how to assess checkpoint function experimentally, and how to interpret common observations in cultured cells.

The Cell Cycle and Its Phases

The cell cycle is the ordered sequence of events through which a cell duplicates its contents and divides into two daughter cells. The cycle is divided into four phases. G1 phase is the first gap phase, during which the cell grows and synthesizes proteins and organelles in preparation for DNA replication. S phase is the synthesis phase, during which the genome is replicated. G2 phase is the second gap phase, during which the cell verifies that DNA replication is complete and repairs any damage before mitosis. M phase is mitosis and cytokinesis, during which chromosomes are segregated and the cell divides. Cells that are not actively dividing may exit the cycle into a quiescent state called G0.

The transitions between these phases are driven by cyclin dependent kinases, or CDKs, which are activated by binding to regulatory subunits called cyclins. Different cyclin CDK complexes are active at different phases. Cyclin D CDK4/6 complexes drive progression through G1, cyclin E CDK2 complexes promote the G1/S transition, cyclin A CDK2 complexes function during S phase, and cyclin B CDK1 complexes drive the G2/M transition and mitosis. The activity of these complexes is opposed by cyclin dependent kinase inhibitors, or CKIs, which can arrest the cell cycle in response to various signals.

Checkpoints are distinct from the core oscillatory machinery of the cell cycle. While cyclin CDK complexes provide the driving force for phase transitions, checkpoints act as surveillance systems that can halt that driving force when conditions are not met. A checkpoint does also slow the cycle, it actively prevents progression until the monitored condition is satisfied. This distinction matters in the laboratory because a compound that inhibits a CDK may produce a different pattern of arrest than a compound that activates a checkpoint kinase.

The G1 Checkpoint

The G1 checkpoint, also called the restriction point in mammalian cells, is the decision point at which a cell commits to completing the cell cycle. Before this checkpoint, cells respond to growth factors and nutrient availability. After passing the checkpoint, cells are committed to DNA replication and division regardless of external signals. The G1 checkpoint assesses cell size, nutrient status, growth factor signaling, and DNA integrity. If conditions are unfavorable, cells may enter G0 or undergo senescence.

The molecular control of the G1 checkpoint centers on the retinoblastoma protein, or Rb, and its regulation by cyclin D CDK4/6 complexes. In quiescent cells, Rb is hypophosphorylated and binds to E2F transcription factors, repressing the expression of genes required for S phase entry. Mitogenic signaling induces the expression of cyclin D, which activates CDK4/6 to phosphorylate Rb. This initial phosphorylation partially relieves E2F repression, allowing expression of cyclin E. Cyclin E CDK2 then completes Rb phosphorylation, fully releasing E2F and driving the expression of S phase genes. This positive feedback loop makes the G1/S transition a switch-like commitment event.

DNA damage at the G1 checkpoint activates the tumor suppressor p53. The ATM and ATR kinases, which sense DNA double strand breaks and replication stress respectively, phosphorylate and activate downstream checkpoint kinases. These kinases phosphorylate p53, stabilizing it and allowing it to accumulate in the nucleus. p53 then transactivates the gene encoding p21, a CKI that inhibits cyclin E CDK2 and cyclin A CDK2 complexes. This inhibition maintains Rb in its hypophosphorylated state and prevents S phase entry. The p53 dependent G1 arrest allows time for DNA repair or, if the damage is irreparable, triggers apoptosis or senescence.

The G1 checkpoint is frequently dysregulated in cancer. The cyclin D CDK4/6 pathway is disrupted in a large majority of melanoma cases, and mutations in genes encoding Rb, p53, or CDK inhibitors are common across tumor types. When the G1 checkpoint is lost, cells rely more heavily on the G2 checkpoint to repair DNA damage before mitosis. This differential reliance has therapeutic implications, as discussed later in this article.

The G2 Checkpoint

The G2 checkpoint operates at the boundary between G2 phase and mitosis. Its primary function is to ensure that DNA replication is complete and that any DNA damage incurred during S phase or G2 is repaired before chromosome condensation and segregation begin. The G2 checkpoint also monitors cell size and the integrity of cellular components required for mitosis.

The key regulator of the G2/M transition is the cyclin B CDK1 complex. Cyclin B accumulates during S and G2 phases, but CDK1 remains inactive until it is dephosphorylated at specific residues by the phosphatase CDC25. The kinases WEE1 and MYT1 phosphorylate CDK1 at inhibitory sites, keeping it inactive. At the G2/M transition, CDC25 removes these inhibitory phosphates, activating CDK1 and triggering entry into mitosis.

DNA damage at the G2 checkpoint activates the ATM and ATR kinases, which phosphorylate and activate the checkpoint kinases CHK2 and CHK1 respectively. These checkpoint kinases phosphorylate and inactivate CDC25, preventing CDK1 activation. They also activate WEE1, promoting inhibitory phosphorylation of CDK1. The net effect is that cyclin B CDK1 remains inactive and the cell is held in G2. In addition, the GADD45 proteins, which are induced by p53, can promote G2 arrest by interfering with cyclin B CDK1 complex formation.

The G2 checkpoint is particularly important in cells that lack a functional G1 checkpoint. Because many cancer cells have lost p53 dependent G1 arrest, they depend on the G2 checkpoint to manage DNA damage. This dependence creates a therapeutic window. Inhibitors of WEE1, CHK1, and ATR can abrogate the G2 checkpoint, forcing cells with DNA damage into mitosis prematurely. This premature entry leads to mitotic catastrophe and cell death. Normal cells with intact G1 checkpoints are relatively spared because they can arrest in G1 instead. This strategy, called synthetic lethality, exploits the differential checkpoint reliance between tumor and normal cells.

The G2 checkpoint also responds to replication stress. When DNA replication forks stall, ATR is activated and signals through CHK1 to stabilize the forks and prevent their collapse. This replication checkpoint is distinct from the G2 DNA damage checkpoint but shares many molecular components. In the laboratory, agents that cause replication stress, such as hydroxyurea, activate this pathway and can arrest cells in S phase or at the G2/M boundary.

The M Checkpoint

The M checkpoint, also called the spindle assembly checkpoint or the mitotic checkpoint, operates during mitosis at the metaphase to anaphase transition. Its function is to ensure that all chromosomes are properly attached to the mitotic spindle and aligned at the metaphase plate before sister chromatids are separated. The checkpoint monitors tension across kinetochores and occupancy of kinetochores by spindle microtubules.

The molecular components of the M checkpoint include the proteins MAD1, MAD2, BUB1, BUB3, BUBR1, and MPS1. These proteins localize to unattached kinetochores and generate a diffusible signal that inhibits the anaphase promoting complex, or APC/C. The APC/C is an E3 ubiquitin ligase that targets securin for degradation. Securin inhibits separase, the protease that cleaves the cohesin rings holding sister chromatids together. When the M checkpoint is satisfied, the APC/C is activated, securin is degraded, separase is released, and cohesin is cleaved, allowing sister chromatids to separate.

The M checkpoint is rarely mutated in cancer, in contrast to the G1 and G2 checkpoints. This is because a defective M checkpoint leads to catastrophic chromosome missegregation and cell death. However, cancer cells may have a weakened M checkpoint that allows low levels of chromosome instability, which can promote tumor evolution. The M checkpoint is also the target of several anticancer drugs, including taxanes and vinca alkaloids, which disrupt spindle dynamics and activate the checkpoint, leading to prolonged mitotic arrest and cell death.

At a Glance: Checkpoint Comparison

Molecular Regulators and Their Functions

The checkpoint pathways share a common architecture. Sensors detect the initiating signal, such as DNA damage or unattached kinetochores. Transducers amplify and propagate the signal. Effectors execute the cellular response, which may be cell cycle arrest, DNA repair, apoptosis, or senescence.

The ATM and ATR kinases are the primary sensors of DNA damage. ATM responds mainly to double strand breaks, while ATR responds to single stranded DNA, which arises at stalled replication forks and during resection of double strand breaks. Both kinases phosphorylate downstream targets, including the histone variant H2AX, which marks damaged chromatin, and the checkpoint kinases CHK2 and CHK1. CHK2 is primarily activated by ATM, while CHK1 is primarily activated by ATR. These checkpoint kinases then phosphorylate a variety of substrates to enforce cell cycle arrest.

The p53 protein is a central node in the DNA damage response. It is a transcription factor that is normally kept at low levels by the ubiquitin ligase MDM2. DNA damage signaling stabilizes p53 by phosphorylating it and disrupting its interaction with MDM2. Stabilized p53 transactivates genes involved in cell cycle arrest, DNA repair, and apoptosis. The p21 CKI is a key p53 target that mediates G1 arrest. p53 also contributes to G2 arrest by inducing GADD45 and other regulators.

The cyclin dependent kinase inhibitors are divided into two families. The INK4 family, including p16, p15, p18, and p19, specifically inhibits CDK4 and CDK6. The CIP/KIP family, including p21, p27, and p57, inhibits cyclin E CDK2 and cyclin A CDK2 complexes. These inhibitors are induced by various stress signals and mediate cell cycle arrest in response to DNA damage, oxidative stress, and contact inhibition.

The WEE1 kinase and the CDC25 phosphatases form a regulatory module that controls CDK1 activity at the G2/M transition. WEE1 phosphorylates CDK1 at inhibitory sites, while CDC25 removes these phosphates. The balance between these opposing activities determines whether the cell enters mitosis. DNA damage signaling tips this balance toward WEE1 activity and CDC25 inactivation, holding the cell in G2.

Experimental Assessment of Checkpoint Function

Laboratory assessment of checkpoint function typically involves exposing cells to a DNA damaging agent or a checkpoint inhibitor and measuring the resulting cell cycle distribution. Flow cytometry is the most common method for this analysis. Cells are fixed, stained with a DNA binding dye such as propidium iodide, and analyzed for DNA content. G1 cells have a 2N DNA content, S phase cells have an intermediate content, and G2/M cells have a 4N content. A population arrested at a checkpoint will accumulate at the corresponding DNA content.

Several experimental approaches can distinguish between G2 arrest and M arrest. Because both G2 and M phase cells have 4N DNA content, flow cytometry alone cannot distinguish them. Phosphorylation of histone H3 at serine 10 is a marker of mitosis, and cells positive for this marker are in M phase. Alternatively, cells can be examined by microscopy for mitotic figures, chromosome condensation, or spindle morphology. The choice of method depends on the question being asked and the equipment available.

Checkpoint function can also be assessed by measuring the phosphorylation of checkpoint proteins. Western blotting for phosphorylated CHK1, CHK2, p53, or H2AX can indicate whether the DNA damage response pathway is active. Immunofluorescence can localize these phosphorylated proteins to sites of damage or to kinetochores. These biochemical readouts complement cell cycle distribution data and provide mechanistic information.

A typical checkpoint assay involves treating cells with a DNA damaging agent, such as ionizing radiation or a radiomimetic drug, and then measuring cell cycle distribution at multiple time points. A functional G1 checkpoint will cause cells to accumulate with 2N DNA content. A functional G2 checkpoint will cause cells to accumulate with 4N DNA content. If both checkpoints are defective, cells will continue to cycle despite DNA damage, and the cell cycle distribution will not change dramatically. The time course is important because cells may initially arrest and then recover as damage is repaired.

Practical Workflow for Checkpoint Studies

A standardized workflow for evaluating checkpoint function in cultured cells includes the following steps. First, confirm the identity and health of the cell line. Cells should be in logarithmic growth and free of mycoplasma contamination. Second, synchronize cells if the experiment requires a defined starting point. Synchronization can be achieved by serum starvation, contact inhibition, or chemical inhibitors, but each method has limitations and can perturb the cell cycle. Third, treat cells with the checkpoint stimulus or inhibitor at the appropriate concentration and duration. Fourth, collect samples at defined time points for analysis. Fifth, analyze cell cycle distribution by flow cytometry and confirm results with a second method, such as microscopy or Western blotting.

Controls are essential in checkpoint experiments. An untreated control establishes the baseline cell cycle distribution. A positive control, such as a known DNA damaging agent, confirms that the assay can detect checkpoint activation. A negative control, such as a checkpoint inhibitor alone, confirms that the assay can detect checkpoint abrogation. Each control should be processed identically to the experimental samples.

The choice of DNA damaging agent affects which checkpoint is engaged. Ionizing radiation and radiomimetic drugs primarily cause double strand breaks and activate ATM and the G1 and G2 checkpoints. UV radiation and replication inhibitors cause replication stress and activate ATR and the S and G2 checkpoints. The dose and duration of treatment determine whether the arrest is transient or sustained. High doses may trigger apoptosis instead of arrest, which complicates interpretation.

Records and Measurements

Documentation of checkpoint experiments should include the cell line, passage number, culture conditions, treatment agent, dose, duration, and time points analyzed. Flow cytometry data should include the percentage of cells in each phase for each condition and time point. Gating strategies should be recorded so that the analysis can be reproduced. Western blot data should include the antibodies used, dilutions, and exposure times. All raw data files should be archived.

Quantitative measurements of checkpoint function can be expressed as the fraction of cells arrested at a particular phase or as the time required for cells to recover from arrest. The mitotic index, defined as the percentage of cells in mitosis, is a useful measure for M checkpoint studies. The percentage of cells with phosphorylated histone H3 can be measured by flow cytometry or immunofluorescence. These measurements allow comparison between cell lines, treatments, and experimental conditions.

Reproducibility requires attention to technical details. Cell density at the time of treatment affects the response to many agents. The passage number of the cell line can influence checkpoint function, particularly in cells that have acquired mutations during prolonged culture. The source and lot of serum and other media components can affect cell cycle progression. These variables should be recorded and controlled where possible.

Common Failure Patterns in Checkpoint Experiments

Several recurring problems can compromise checkpoint experiments. A common issue is the failure to distinguish G2 arrest from M arrest. Because both populations have 4N DNA content, flow cytometry alone cannot resolve them. This can lead to incorrect conclusions about which checkpoint is active. Including a mitotic marker, such as phosphorylated histone H3, resolves this ambiguity.

Another common issue is the use of too high a dose of DNA damaging agent. High doses can trigger apoptosis before the checkpoint response is fully established, producing a cell cycle profile that reflects cell death instead of arrest. Dose response experiments can identify the range over which arrest occurs without significant apoptosis. The appearance of a sub-G1 population, which indicates apoptotic cells with fragmented DNA, signals that the dose is too high.

Checkpoint inhibitors can produce misleading results if their specificity is not confirmed. Many kinase inhibitors have off target effects at the concentrations used. Genetic approaches, such as small interfering RNA or CRISPR mediated knockout, can confirm the role of a specific kinase. Combining pharmacological and genetic approaches provides stronger evidence than either alone.

Cell synchronization can introduce artifacts. Chemical synchronization agents, such as thymidine or nocodazole, can themselves activate checkpoints or cause DNA damage. The recovery period after synchronization should be optimized to allow cells to resume normal cycling before treatment. The choice of synchronization method should be justified based on the experimental question.

Limitations of Checkpoint Assays

Checkpoint assays measure population averages and may not capture heterogeneity in the response of individual cells. Live cell imaging can reveal the dynamics of checkpoint activation and recovery at the single cell level, but this approach requires specialized equipment and analysis software. Population based assays may miss subpopulations of cells that behave differently from the majority.

The cell cycle distribution measured by flow cytometry is a snapshot at a single time point. The response to a checkpoint stimulus is dynamic, with cells entering and leaving arrest over time. Time course experiments are necessary to capture this dynamics. The choice of time points should be based on the cell cycle length of the cell line and the expected kinetics of the response.

Checkpoint function in cultured cells may not reflect checkpoint function in vivo. The tissue microenvironment, including oxygen tension, nutrient availability, and interactions with other cell types, can influence checkpoint responses. Results from cell culture experiments should be interpreted with this limitation in mind. Studies in animal models or patient samples may be needed to confirm findings with clinical relevance.

The distinction between checkpoint activation and checkpoint adaptation is important. Checkpoint activation refers to the initial arrest in response to a stimulus. Checkpoint adaptation refers to the resumption of cell cycle progression despite persistent damage. Cells that adapt may enter mitosis with unrepaired DNA damage, leading to genomic instability. Assays that measure only the initial arrest may miss adaptation if the time course is too short.

Checkpoint Dysregulation in Disease

Dysregulation of cell cycle checkpoints is a hallmark of cancer. Genetic mutations can drive tumor onset by augmenting cell division rates or by disabling the normal controls of cell cycle arrest and apoptosis. Tumor cells often have defective DNA damage checkpoints in G1, S, and G2, allowing cell division despite the accumulation of genetic errors. This loss of checkpoint function contributes to the genomic instability that characterizes many cancers.

The pattern of checkpoint dysfunction varies between tumor types. The G1/S transition mediated by the cyclin D CDK4/6 pathway is dysregulated in a large majority of melanoma cases. Pan cancer analyses have shown that the G2/M checkpoint pathway is inhibited in many cancer types compared to normal tissue, while other DNA repair pathways are upregulated. This pattern suggests that cancer cells suppress the G2/M checkpoint while maintaining other repair mechanisms.

Some checkpoints are rarely mutated in cancer because their loss is lethal. The DNA replication stress checkpoint and the mitotic checkpoint remain intact in most tumors because any aberrant activity could result in irreparable damage or catastrophic chromosome missegregation leading to cell death. Tumors may become dependent on these checkpoints for survival, creating vulnerabilities that can be exploited therapeutically.

Checkpoint dysfunction also contributes to hereditary diseases. Mutations in genes encoding checkpoint proteins can cause developmental abnormalities, immunodeficiency, and increased cancer susceptibility. The study of these rare genetic disorders has provided insight into the normal functions of checkpoint pathways. Understanding these connections is important for diagnostic professionals who may encounter patients with these conditions.

Therapeutic Targeting of Checkpoints

The differential reliance of cancer cells on specific checkpoints has led to the development of checkpoint inhibitors as anticancer agents. Inhibitors of WEE1, CHK1, and ATR are being investigated for use in combination with radiation and genotoxic chemotherapy. These inhibitors abrogate the G2 checkpoint, forcing tumor cells with DNA damage into mitosis prematurely. The resulting mitotic catastrophe kills the tumor cells, while normal cells with intact G1 checkpoints are relatively spared.

The combination of checkpoint inhibitors with DNA damaging agents is based on the principle of synthetic lethality. Tumor cells that lack the G1 checkpoint rely on the G2 checkpoint to repair DNA damage. Inhibiting the G2 checkpoint in these cells while simultaneously inducing DNA damage creates a situation in which the cells cannot repair the damage and cannot arrest to avoid mitosis. This combination is selectively toxic to tumor cells.

Checkpoint inhibitors also affect DNA repair pathways directly. Inhibition of WEE1, CHK1, or ATR suppresses homologous recombination repair, which is required for the accurate repair of double strand breaks. This suppression can sensitize tumor cells to agents that cause double strand breaks, such as ionizing radiation. The combination of checkpoint inhibition and radiation may also enhance antitumor immune responses.

The M checkpoint is targeted by drugs that disrupt spindle dynamics. Taxanes stabilize microtubules, while vinca alkaloids destabilize them. Both classes of drugs activate the M checkpoint by preventing proper chromosome attachment to the spindle. The prolonged mitotic arrest that results can trigger apoptosis. Resistance to these drugs can arise through mutations that weaken the M checkpoint or through overexpression of drug efflux pumps.

Safety and Regulatory Context

Work with cell cycle checkpoint inhibitors and DNA damaging agents requires appropriate safety precautions. Many of these compounds are genotoxic and should be handled in a biosafety cabinet with appropriate personal protective equipment. The Laboratory Biosafety Manual from the World Health Organization provides guidance on safe handling of biological materials and hazardous chemicals. Institutional biosafety committees and chemical safety officers can provide specific guidance for the agents used in a particular laboratory.

The Laboratory Quality Management System Handbook from the World Health Organization emphasizes the importance of documentation, standard operating procedures, and quality control in laboratory testing. These principles apply to research laboratories as well as clinical diagnostic laboratories. Checkpoint assays should be performed according to written protocols, with appropriate controls and documentation. Results should be reviewed by qualified personnel before they are used to support conclusions.

Diagnostic applications of checkpoint analysis require validation according to established guidelines. The Bioanalytical Method Validation Guidance from the U.S. Food and Drug Administration describes the parameters that should be evaluated when validating a quantitative analytical method, including accuracy, precision, selectivity, and stability. The Assay Guidance Manual from the National Center for Advancing Translational Sciences provides practical guidance for developing and validating assays for drug discovery. These resources are relevant for laboratories developing checkpoint assays for diagnostic or translational research purposes.

Professional Escalation Criteria

Laboratory personnel should escalate unexpected results to a supervisor or principal investigator. Results that are inconsistent with established literature, that cannot be reproduced, or that suggest a problem with the assay should be reviewed before conclusions are drawn. Unexpected toxicity or unusual cell behavior after treatment with a checkpoint inhibitor should be reported to the appropriate safety officer.

Clinically relevant findings should be escalated to the appropriate healthcare professional. If checkpoint analysis is performed on patient samples, results should be interpreted in the context of the patient's clinical history and other laboratory findings. Abnormal results should be confirmed by repeat testing before they are reported. The limitations of the assay should be communicated clearly to the requesting clinician.

Frequently Asked Questions

What is the difference between the G1 checkpoint and the restriction point?

The restriction point is the specific point in G1 after which a mammalian cell no longer requires growth factors to complete the cell cycle. The G1 checkpoint is a broader concept that includes the restriction point as well as the DNA damage checkpoint that operates at the G1/S boundary. The restriction point is primarily regulated by the Rb and E2F pathway, while the DNA damage checkpoint at G1/S is mediated by p53 and p21. In practice, the terms are sometimes used interchangeably, but they refer to distinct regulatory mechanisms.

How can I distinguish G2 arrest from M arrest in flow cytometry?

Flow cytometry alone cannot distinguish G2 from M phase because both have 4N DNA content. To distinguish them, stain cells with an antibody against phosphorylated histone H3, which is present only in mitotic cells. Cells that are 4N and positive for phosphorylated histone H3 are in M phase, while cells that are 4N and negative are in G2. Alternatively, examine cells by microscopy for mitotic figures or chromosome condensation.

Why do cancer cells rely more on the G2 checkpoint than normal cells?

Many cancer cells have lost the p53 dependent G1 checkpoint through mutation or inactivation of p53 or other components of the pathway. Without a functional G1 checkpoint, these cells cannot arrest in G1 in response to DNA damage. They therefore depend on the G2 checkpoint to halt the cell cycle and allow DNA repair before mitosis. This differential reliance is the basis for therapeutic strategies that target the G2 checkpoint in cancer cells.

What is the spindle assembly checkpoint?

The spindle assembly checkpoint, also called the M checkpoint, is a surveillance mechanism that operates during mitosis. It monitors the attachment of chromosomes to the mitotic spindle and the tension across kinetochores. The checkpoint delays the metaphase to anaphase transition until all chromosomes are properly attached and aligned. When the checkpoint is satisfied, the anaphase promoting complex is activated, leading to sister chromatid separation.

What happens when the G2 checkpoint is abrogated?

When the G2 checkpoint is abrogated, cells with DNA damage enter mitosis prematurely. This premature entry can lead to mitotic catastrophe, a form of cell death that occurs when cells attempt to divide with damaged or incompletely replicated DNA. Checkpoint inhibitors such as WEE1, CHK1, and ATR inhibitors can abrogate the G2 checkpoint. This strategy is being investigated as a way to selectively kill cancer cells that lack the G1 checkpoint.

How do I choose the right DNA damaging agent for a checkpoint experiment?

The choice of DNA damaging agent depends on which checkpoint you want to study. Ionizing radiation and radiomimetic drugs cause double strand breaks and activate ATM and the G1 and G2 checkpoints. UV radiation and replication inhibitors cause replication stress and activate ATR and the S and G2 checkpoints. The dose should be determined empirically to produce a robust arrest without excessive apoptosis. A dose response experiment is recommended.

What controls should I include in a checkpoint assay?

An untreated control establishes the baseline cell cycle distribution. A positive control, such as a known DNA damaging agent, confirms that the assay can detect checkpoint activation. A negative control, such as a checkpoint inhibitor alone, confirms that the assay can detect checkpoint abrogation. Each control should be processed identically to the experimental samples. Including a mitotic marker helps distinguish G2 from M arrest.

Can checkpoint analysis be used in clinical diagnostics?

Checkpoint analysis is primarily a research tool, but it has potential diagnostic applications. Assessment of checkpoint function in patient derived tumor cells could inform treatment decisions, particularly for therapies that target checkpoint kinases. However, these assays require validation according to established guidelines before they can be used clinically. The Bioanalytical Method Validation Guidance from the U.S. Food and Drug Administration and the Assay Guidance Manual from the National Center for Advancing Translational Sciences provide relevant guidance.

Related Diagnostic Guides

• How to Calculate Cell Concentration Using a Hemocytometer
• Polyacrylamide Gel Electrophoresis vs Agarose Gel Electrophoresis: Key Differences
• How to Store and Handle Chemical Reagents for Molecular Biology
• How to Calculate the Number of Cells in a Confluent Monolayer
• How to Store and Handle Antibiotics for Cell Culture and Selection

References and Further Reading

• Laboratory Quality Management System Handbook. World Health Organization.
• Laboratory Biosafety Manual. World Health Organization.
• Assay Guidance Manual. National Center for Advancing Translational Sciences.
• Bioanalytical Method Validation Guidance. U.S. Food and Drug Administration.
• NCBI Literature Resources. National Center for Biotechnology Information.
• Cell cycle regulation by checkpoints.. Methods in molecular biology (Clifton, N.J.), 2014.
• Cell cycle dysregulation in cancer.. Pharmacological reviews, 2025.
• Targeting cell cycle regulation via the G2-M checkpoint for synthetic lethality in melanoma.. Cell cycle (Georgetown, Tex.), 2021.
• The involvement of cyclin-dependent kinase 7 (CDK7) and 9 (CDK9) in coordinating transcription and cell cycle checkpoint regulation.. Cell cycle (Georgetown, Tex.), 2024.
• A cell cycle checkpoint for the endoplasmic reticulum.. Biochimica et biophysica acta. Molecular cell research, 2020.
• Cell cycle checkpoint control in response to DNA damage by environmental stresses.. The Plant journal : for cell and molecular biology, 2022.
• Expanding roles of cell cycle checkpoint inhibitors in radiation oncology.. International journal of radiation biology, 2023.
• Checkpoint kinase 1 in DNA damage response and cell cycle regulation.. Cellular and molecular life sciences : CMLS, 2013.
• Dibutyl phthalate induces DNA damage and activates ATM-Chk2-p53 signaling to disrupt the prepubertal blood-testis barrier.. 2026.
• Oxidative base damage to telomeres sensitizes cancer cells to ATR inhibition.. 2026.
• Tumor cell cycle regulation: integrated perspective of stage characteristics, regulatory networks, and signaling pathway intervention strategies.. 2026.
• Pan-cancer antagonistic inhibition pattern of ATM-driven G2/M checkpoint pathway vs other DNA repair pathways.. DNA Repair, 2023.
• Cancer cells employ nuclear caspase-8 to overcome the p53-dependent G2/M checkpoint through cleavage of USP28. Molecules and Cells, 2020.
• Downregulation of Cell Cycle and Checkpoint Genes by Class I HDAC Inhibitors Limits Synergism with G2/M Checkpoint Inhibitor MK-1775 in Bladder Cancer Cells. Genes, 2021.
• The impact of a negligent G2/M checkpoint on genomic instability and cancer induction. Nature Reviews. Cancer, 2007.
• Enhancing Therapeutic Response and Overcoming Resistance to Checkpoint Inhibitors in Ovarian Cancer through Cell Cycle Regulation. International Journal of Molecular Sciences, 2024.
• Regulation of mitotic exit by cell cycle checkpoints: Lessons from Saccharomyces cerevisiae. Genes, 2020.
• Inhibitory targeting of checkpoint kinase signaling overrides radiation-induced cell cycle gene regulation: A therapeutic strategy in tumor cell radiosensitization?. Radiotherapy and Oncology, 2004.

This article is educational and does not replace validated laboratory procedures, institutional biosafety review, manufacturer instructions, or professional interpretation.